PLN and ocular melanoma: Based on the observed effects of R14del-PLN on contractile parameters, we examined whether the myosin-specific pharmaceutical activator omecamtiv mecarbil (OM, Figure 2) could reverse R14del-PLN-mediated contractile dysfunction and improve the contractile properties of 3-month-old cardiomyocytes in vitro.